Gibson Dunn Represented Cytokinetics in $805 Million Offering of Common Stock
Firm News | May 11, 2026
Gibson Dunn represented Cytokinetics, Incorporated in a public offering of 11,338,028 shares of common stock, including the full exercise of the underwriters’ option to purchase an additional 1,478,873 shares. The offering generated aggregate gross proceeds of approximately $805 million to Cytokinetics. Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan, and Jefferies acted as joint book-running managers for the offering.
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.
The firm’s team included partners Ryan Murr and Branden Berns, of counsel Marie Kwon, and associates Jasmine Vitug and Kriti Hannon.